TrumpRx Falls Short: Supermarket Promise, Boutique Reality
Nearly six months after its launch, TrumpRx — the Trump administration’s flagship prescription drug discount website — has fallen well short of its promise to bring “supermarket-style competition” to American drug pricing. According to an NPR analysis, the site offers just 92 brand-name drugs from 15 participating pharmaceutical companies, representing fewer than 12% of the more than 800 brand-name drugs those companies have on the market. Critics say the program functions less like a discount supermarket and more like a high-priced boutique with limited selection.
The Promise vs. Reality
TrumpRx launched on February 5, 2026, with 43 drugs from five companies. President Donald Trump declared at the launch event: “It’s the biggest thing to happen in healthcare, I think, in many, many decades.” The website was the culmination of a May 2025 executive order aimed at bringing American drug prices in line with other wealthy countries, followed by letters to 17 drug companies threatening tariffs if they did not voluntarily lower prices.
By mid-July 2026, the site had expanded to 92 brand-name drugs — but the numbers tell a sobering story. Pfizer, which has the most drugs on TrumpRx with 30 listings, offers only a fraction of its portfolio of at least 178 brand-name drugs. Some of Pfizer’s top revenue-generating medications — including the blood thinner Eliquis, the breast cancer drug Ibrance, and the COVID treatment Paxlovid — are absent from the platform entirely.
A Sparse Menu
Gilead and Regeneron both announced agreements with the administration but still have no drugs listed on TrumpRx as of mid-July, according to NPR. The companies say they plan to add one drug each — Gilead’s Epclusa for hepatitis C and Regeneron’s Praluent for bad cholesterol — but no timeline has been set.
“The key takeaway is that most of these companies are doing this for a small number of products and in a limited setting,” Dr. Ben Rome, a health policy researcher and physician at Brigham and Women’s Hospital, told NPR. “They’re not engaging to do this on a large scale.”
Boston University health economist Rena Conti echoed that assessment: “The companies are offering deals on the products that they choose, not the universe of products that they offer. And that consequently sounds good and may help a small share of people who are purchasing these products at a cash price but are not helping all the consumers of their products.”
Generic Competition Undercuts ‘Presidential Deals’
In May 2026, TrumpRx added hundreds of generic drugs through partnerships with Amazon Pharmacy, GoodRx, and Cost Plus Drugs. The site now features over 800 medications total. However, an NPR investigation found that at least some of the 79 “presidential deal” brand-name drugs have generic competition that offers better value.
For example, Pristiq, a Pfizer drug for major depressive disorder, is listed as a presidential deal on TrumpRx for $200.10, but its generic can be purchased for $20 to $30 with a GoodRx coupon. Meanwhile, Merck’s blockbuster cancer drug Keytruda — one of the most important drugs on the market — is not available on TrumpRx at all.
Who Actually Benefits?
The program does deliver genuine savings for specific patient populations. Patients undergoing fertility treatments, who often pay out of pocket, can save up to $2,000 per cycle. Those seeking GLP-1 weight-loss drugs like Ozempic and Wegovy are the most common users of TrumpRx discounts, according to GoodRx, which provides the site’s coupon infrastructure.
But for the vast majority of insured Americans, using their existing health insurance remains a better deal than TrumpRx cash prices. “That is not the majority of prescription drugs,” Rome said. “It’s not the majority of patients who need prescription drugs.”
Transparency and Verification Concerns
The TrumpRx website claims to have saved Americans more than $400 million, but that statistic has not been updated in over a month and is difficult to verify independently. NPR reported that the White House did not respond to questions about how many patients have used the site or which drugs are purchased most frequently.
A YouGov poll from February 2026 found that the program’s branding is itself polarizing: when described without the TrumpRx name, the program enjoys 57% approval. When the name is attached, approval drops to 41%. Among Democrats, approval falls from 45% to just 13%.
What’s Next?
Despite its limitations, TrumpRx has reshaped the pharmaceutical landscape by securing voluntary agreements from 17 major drugmakers representing roughly 86% of the branded U.S. pharmaceutical market. The White House has framed the program as a signature achievement, and President Trump has called it “the greatest breakthrough in lowering health care costs in modern history.”
However, whether the program will expand to include the blockbuster drugs that patients actually need — and whether the promised savings will materialize for more than a narrow slice of Americans — remains an open question. As Pfizer spokesperson Kat Romaniuk told NPR: “We will continue to make regular assessments and adjustments as the program evolves.”